Cipla’s results for 4QFY2016 have come much below our expectations. Sales
came in at Rs3,207cr V/s Rs3,274cr expected, a yoy growth of 7.6%. The sales
growth was driven by domestic formulations (Rs1,258cr), as expected, which grew
15.9% yoy, while exports posted a yoy growth of 7.4%. On the operating front,
the EBDITA came in at 5.0% V/s 13.3% in 4QFY2015 and against 13.8%
expected. The reported EBDITA margins include a lot of one-offs, adjusting for
which the OPM was at 15.8%. The net profit thus came in at Rs81cr V/s Rs399cr
expected and V/s Rs260cr in 4QFY2015, a yoy de-growth of 68.9%. We remain
Neutral on the stock.
Results much lower than expectations: Sales for the quarter came in at Rs3,207cr
V/s Rs3,274cr expected, a yoy growth of 7.6%. The sales growth was driven by
domestic formulations (Rs1,258cr), as expected, which grew 15.9% yoy, while
exports posted a yoy growth of 7.4%. Exports of formulations increased 3.2% to
Rs1,744cr during 4QFY2016, while exports of APIs were flat at Rs204cr during
4QFY2016. On the operating front, the EBDITA came in at 5.0% V/s 13.3% in
4QFY2015 and against 13.8% expected. The decline was mainly owing to a dip
in gross profit margins, which came in at 55.8% V/s 61.1% in 4QFY2015. The
reported EBDITA margins include a lot of one-offs, adjusting for which, the OPM
was 15.8%. The net profit thus came in at Rs81cr V/s `399cr expected and V/s
Rs260cr in 4QFY2015, a yoy dip of 68.9%.
Outlook and valuation: We expect the company to post a 16.3% CAGR in
net sales to Rs18,089cr and EPS to record a 20.4% CAGR to Rs27.2 over
FY2016–18E. We recommend our neutral stance on the stock owing to the
company’s poor return ratios.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...